Currently, there are no effective, broad-spectrum, pan-coronavirus drugs on the market as of today. Even as President Joe Biden has called to end the Covid-19 emergency, the pandemic still continues on as Covid continues to take lives and evolve.
Traditional drug development methodologies have not resulted in an effective drug against SARS-CoV-2 variants… In fact, the vaccines are only effective for approximately 3-6 months…. NanoViricides therapeutic drugs are dramatically different.
With NV-CoV-2, the Company targets their drug to fulfill that unmet medical need. Currently, there is still no antiviral COVID drug available that can be used for the treatment of all patients. Even more concerning, there is no antiviral COVID drug available that can successfully attack the evolving variants.
With two Covid drug candidates in development, the Company’s approach is novel as both drugs are found to be significantly superior to Remdesivir (the only approved drug for severe, hospitalized cases) in lethal SARS-emulating coronavirus infection animal studies!
The Company’s novel approach has already enabled variant-proof drugs, blocking the complete viral life cycle without requiring help from the host’s own defense systems! If both the viral re-infection cycle, and viral replication cycle arms of the viral lifecycle are blocked, a cure for many viral diseases is possible!!
The Company’s virus-specific nanoviricides have been created against important viruses such as HIV, Influenza and Bird Flu by choosing highly virus-specific ligands.
Broad-spectrum nanoviricides have been created that can bind to possibly as many as 90-95% of known viruses. The Company is developing broad-spectrum nanoviricides to combat several neglected tropical diseases, such as Dengue, Rabies, and Ebola/Marburg.
Antibodies have been developed as drugs against viruses. However, each antibody only binds by two points to the virus, and destruction of the complex requires effective immune function, which is not the case in sickness.
Vaccines only train the body into producing antibodies against the virus in the vaccine. Antibodies and vaccines are easily overcome by viruses by mutating in the field, hence the need for annual influenza vaccine updates.
NanoViricides destroy viruses and their variants without relying on the patient's immune system.
The company is developing nanotechnology-based biomimetic anti-viral medicines, called “nanoviricides.” In contrast to immunizations, A nanoviricide is a Nanomachine that completes the task of destroying a virus WITHOUT the help of the patient’s immune system.
This solves the key issues of drug resistance from viral mutations as nanoviricides drugs are empowered by biomimetic technology.
Designed by NanoViricides to “fool” a virus, the nanoviricides attach to the agent in the same way that the virus normally attaches to receptors on a cell surface. The nanoviricide dismantles and eliminates the virus’ effect on the host by directly attacking the virus at multiple points.
NanoViricides, Inc. is a global leader in the development of nanomedicine drugs against viruses. The Company’s unique nanoviricide® platform technology defines a novel mechanism enabling first-in class drugs against viruses including Covid-19.
NV-CoV-2 is a broad-spectrum, pan-coronavirus drug that has the exciting potential to overcome SARS-CoV-2 variants. Additionally, NV-CoV-2 has shown extremely strong safety in multiple pre-clinical animal models in both GLP and non-GLP studies.
The observed strong pre-clinical safety of NV-CoV-2 indicates that the drug would be applicable to treat disease in all populations from pediatrics to otherwise healthy adults to patients with co-morbidities.
NV-CoV-2 has shown broad-spectrum, pan-coronavirus activity. The drug has shown strong effectiveness in animal models that used ACE2-Binding coronavirus causing lethal lung infection emulating SARS-CoV-2 clinical disease.
Effective against all tested, unrelated, coronaviruses, this means NV-CoV-2 can remain effective against SARS-CoV-2 emerging variants for a very long time!
NV-CoV-2 is expected to be available in the form of oral gummies or syrup for mild to moderate disease which makes it easy to administer to a broad range of patients from children to older adults!
Recently, the NV-CoV-2 oral syrup and gummies drug products were shipped in preparation of impending human clinical trials with Karveer, the Company’s collaborator.
NanoViricides’ promising developments of these diverse products are projected to meet the individual and personalized needs of patients through these effective and accessible treatments.
NanoViricides, Inc.’s promising pipeline is targeting a multi-billion antiviral therapy market…
The 2020 pandemic made the anti-viral market boom with the global antiviral drugs market size to be valued at USD 60.0 billion by 2028!
In particular,, NanoViricides HerpeCide™ Program has its first drug candidate for treatment of shingles, NV-HHV-101, within a topical cream.
The market size for this program is more than ~$10Bn, with the market size for NV-HHV-101 estimated at between $0.5Bn~$2Bn by independent market studies.
NanoViricides, Inc. programs address large markets within the antiviral space that could change the way viruses are treated globally, and result in market size explosions.
Using the nanoviricides® platform technology, NanoViricides, Inc.has developed drug candidates that target a fruitful and expansive market as the company attacks the world’s most pervasive viruses.
With anticipated market explosion on the horizon, NanoVericide’s anti-Herpes drugs franchise, FluCide franchise, and other pipeline products could reap the benefits of this market boom.
Setting its sights on expanding its current portfolio with COVID-19 drug candidates, NanoViricides has already established itself as a transformative leader in the antiviral market.
Creator and developer of nanomedicine technologies, Dr. Anil R. Diwan co-founded NanoViricides and currently serves as the company’s President and Executive Chairman. Diwan has over 35+ years of experience in entrepreneurship and bio-pharmaceutical R&D, including the invention of novel polymeric micelle-based nanomedicine technologies in 1991, the birth of NanoViricides, Inc in 2005, the uplisting from OTC to NYSE-mkt in 2013, and now the first clinical trials of its COVID-19 drug in 2023. Along the way, Dr. Diwan has led several of the finance efforts and has raised over 60+ MM in equity financing since 2010 and has over 60 patents issued internationally resulting from three fundamental international patent applications.
Before that, he has won several NIH SBIR (Small business innovation research) grant awards and holds a Ph.D. from Rice University, Tx, a B.Tech. from Indian Institute of Technology, Mumbai (IIT-B), India where he held high scholastic ranks.
Upon these developments, consumers are projected to accept these drug products as they will offer greater personalization and accessibility to combating and eradicating viral infections even when viruses mutate.
There is no denying that the world is changing… viruses are becoming more rampant and being ahead of the problem makes NNVC an exciting NYSE company that could see unstoppable growth ahead!
NanoViricides, Inc.’s innovative platform technology, R&D agility, flexible cGMP compliant facility, highly effective management team, and extensive anti-viral experience should place this company at the top of your “invest” watchlist!
THIS IS A PAID ADVERTISEMENT
NO INVESTMENT ADVICE
This website is wholly owned by tradigital marketing group, inc. (d/b/a “tradigital ir”). Our reports are advertorials and are for general information purposes only. never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. The disclaimer is to be read and fully understood before using our services, joining our email list, as well as any social networking platforms we may use. please note well: tradigital ir and its employees are not registered investment advisors, broker-dealers, or member(s) of any association for other research providers in any jurisdiction whatsoever. release of liability: through use of this website, viewing or using you agree to hold tradigital ir, its operators, owners, and employees harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damage (monetary or otherwise), or injury (monetary or otherwise) that you may incur. The information contained herein is based on sources that we believe to be reliable but is not guaranteed by us as being accurate and does not purport to be a complete statement or summary of the available data. tradigital ir encourages readers and investors to supplement the information in these reports with independent research and other professional advice. all information on featured companies is provided by the companies profiled or is available from public sources and tradigital ir makes no representations, warranties, or guarantees as to the accuracy or completeness of the disclosure by the profiled companies. none of the materials or advertisements herein constitute offers or solicitations to purchase or sell securities of the companies profiled herein and any decision to invest in any such company or other financial decisions should not be made based upon the information provided herein. instead, tradigital ir strongly urges you to conduct a complete and independent investigation of the respective companies and consideration of all pertinent risks. tradigital ir’s full disclosure is to be read and fully understood before using tradigital ir's website, or joining tradigital ir's email or text list. From time to time, tradigital ir will disseminate information about a company via website, email, sms, and other points of media. By viewing tradigital ir's website and/or reading tradigital ir's email or text newsletter you are agreeing ----> https://tradigitalir.com/disclaimer-tmg/. all potential percentage gains discussed in any communications are based on calculations from the low to the high of the day. We are engaged in the business of marketing and advertising companies for monetary compensation. in compliance with section 17(b) of the securities act we are disclosing that we have been compensated a fee pursuant to an agreement between tradigital and nanoviricides, inc. tradigital was hired for a period beginning august 2019 and ending november 2019 to publicly disseminate information about nanoviricides, inc., via website, email, and sms. We were paid five thousand usd each month, via ach. We owned sixty thousand restricted common shares of nanoviricides, inc., which were eligible for sale on 02/13/2020. We sold this entire position as of 3/4/2022. tradigital was hired for a period beginning january 2020 and ending january 2021 to publicly disseminate information about nanoviricides, inc., via website, email, and sms. We were paid five thousand usd each month, via ach. We owned fifty thousand restricted common shares of nanoviricides, inc., which were eligible for sale on 06/02/2020. We sold this entire position as of 3/4/2022. tradigital was hired to publicly disseminate information about nanoviricides, inc., via website, email, and sms. We were paid twenty-five thousand usd, via ach in february 2022 and the marketing will last for thirty days. We do not own any shares of nanoviricides, inc. Readers are advised to review sec periodic reports: forms 10-q, 10k, form 8-k, insider reports, forms 3, 4, 5 schedule 13d. tradigital ir is compliant with the can-spam act of 2003. tradigital ir does not offer investment advice or analysis, and tradigital ir further urges you to consult your own independent tax, business, financial, and investment advisors. investing in micro-cap, small-cap, and growth securities is highly speculative and carries an extremely high degree of risk. it is possible that an investor's investment may be lost or impaired due to the speculative nature of the companies profiled.the private securities litigation reform act of 1995 provides investors a safe harbor in regard to forward-looking statements. any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events, or performance are not statements of historical fact may be forward-looking statements. forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. forward-looking statements in this action may be identified through the use of words such as projects, foresee, expects, will, anticipates, estimates, believes, understands, or that by statements indicating certain actions & quotes; may, could, or might occur. understand there is no guarantee past performance will be indicative of future results in preparing this publication, tradigital ir has relied upon information supplied by its clients, as well as its clients’ publicly available information and press releases which it believes to be reliable; however, such reliability can not be guaranteed. investors should not rely on the information contained on this website. rather, investors should use the information contained in this website as a starting point for doing additional independent research on the featured companies. The advertisements in this website are believed to be reliable, however, tradigital ir and its owners, affiliates, subsidiaries, officers, directors, representatives, and agents disclaim any liability as to the completeness or accuracy of the information contained in any advertisement and for any omissions of materials facts from such advertisement. tradigital ir is not responsible for any claims made by the companies advertised herein, nor is tradigital ir responsible for any other promotional firm, its program, or its structure. tradigital ir is not affiliated with any exchange, electronic quotation system, the securities exchange commission, or finra.